Concordance Between ctDNA Assay and FoundationOne
Study of Concordance Between Circulating Tumor DNA Assay and Foundation One Tissue Analysis For Genomic Alterations
Sponsor: Avera Cancer Institute
This observational or N/A phase trial investigates Cancer and Circulating Tumor DNA and is currently completed. Avera Cancer Institute leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Sep 2019 — Jan 2021 [monthly]
Completed
-
Aug 2018 — Sep 2019 [monthly]
Completed
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Avera Cancer Institute
- Comprehensive Blood and Cancer Center
- Cone Health
- Eastchester Center for Cancer Care
- Foundation Medicine
- Hematology Oncology Associates of Fredericksburg
- Illinois CancerCare
- Johns Hopkins University
- Mary Crowley Cancer Research Center
- Memorial Sloan Kettering Cancer Center
- Montefiore Medical Center
- Nebraska Cancer Specialists
- Northeast Georgia Medical Center
- Oncology Consultants
- Oncology Hematology Care, Inc
- Prisma Health-Upstate
- Quincy Medical Group
- Rutgers Cancer Institute of New Jersey
- Sanford Health
- Texas Health
- University of California, Davis
- University of California, San Diego
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Cambridge, United States